Bio Blast Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bio Blast Pharma Ltd.
How To Get 270 Approvals At Once? – Stealth's Rare Disease Strategy
With FDA’s blessing, Stealth BioTherapeutics is working toward a pivotal trial that would address an underlying cause, mitochondrial myopathy, of roughly 270 very rare diseases, potentially leading to an aggregate approval in all of those unmet medical needs.
Start-Up Execs On The Move, March 2015
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Execs On The Move, March 2015
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes
The year was marked by record levels of biopharma M&A activity and a strong IPO market. Measures designed to deliver early access to new medicines continued to advance on both sides of the Atlantic, while pricing came in for renewed attention as new, highly effective but extremely expensive products reached the market.
- Large Molecule
- Other Names / Subsidiaries
- Enlivex Therapeutics Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.